Mitsubishi Tanabe Ph (MTZXF) 13.9300 $MTZXF
Global Generic Drugs Market 2014-2018
PR Newswire Europe - Thu May 01, 8:16AM CDT
DUBLIN, May 1, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/sdjlqk/global_generic [http://www.researchandmarkets.com/research/sdjlqk/global_generic]) has announced the addition of the "Global Generic Drugs Market 2014-2018" [http://www.researchandmarkets.com/research/sdjlqk/global_generic] report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 [http://photos.prnewswire.com/prnh/20130307/600769]
Research and Markets: Global Amyotrophic Lateral Sclerosis Market 2014-2018 with Covis Pharmaceutical, Eisai, GSK & Mitsubishi Tanabe Pharma Dominating
Business Wire - Tue Apr 22, 5:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dnrs39/global) has announced the addition of the "Global Amyotrophic Lateral Sclerosis Market 2014-2018 with Covis Pharmaceutical, Eisai, GSK & Mitsubishi Tanabe Pharma Dominating" report to their offering.
Global Amyotrophic Lateral Sclerosis Market 2014-2018 with Covis Pharmaceutical, Eisai, GSK & Mitsubishi Tanabe Pharma Dominating
M2 - Tue Apr 22, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8ckvd2/global) has announced the addition of the "Global Amyotrophic Lateral Sclerosis Market 2014-2018 with Covis Pharmaceutical, Eisai, GSK & Mitsubishi Tanabe Pharma Dominating" report to their offering. One of the main drivers in this market is the increase in the aging population. The number of patients suffering from ALS is increasing due to its relatively high prevalence in the elderly population. The acceptability of ALS drugs is expected to rise due to increasing public awareness of ALS and associated disorders. This is expected to result in increasing drug penetration. Rising general awareness about ALS has led to an increase in research funding and support for clinical and support services. For instance, May is celebrated as ALS awareness month. The ALS Association strives to involve and engage patients and families in the process of increasing awareness and advocating for legislative changes. Similarly, CDMRP also organizes the ALS Research Program. The global research effort through this program has helped increase the number of scientists working on ALS, advanced new discoveries and treatments, and has shed light on the complex genetic and environmental factors involved in ALS. Further, the report states that one of the main challenges is the patent expiry of Rilutek. The patent expiry of Rilutek, the only marketed drug for the treatment of ALS, will result in the loss of market exclusivity. Key vendors dominating this space include - Covis Pharmaceutical Inc. - Eisai Co. Ltd. - GlaxoSmithKline plc - Mitsubishi Tanabe Pharma Corp. Other vendors mentioned in the report are - Amorfix Life Sciences Ltd. - BrainStrom Cell Therapeutics Inc. - Newron Pharmaceuticals S.p.A - Neuraltus Pharmaceuticals Inc. - Nutra Pharma Corp. - Oxford BioMedica plc - Pharnext SAS - Q-Therapeutics Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Buying Criteria - Rate of Incidence and Prevalence - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Late Stage Pipeline Snapshot - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/8ckvd2/global
Research and Markets: Global Diabetic Nephropathy Market 2014-2018 with Merck & Co, Mitsubishi Tanabe Pharma, Novartis AG & Sanofi S.A. Dominating
Business Wire - Wed Apr 09, 8:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pbwmcj/global_diabetic) has announced the addition of the "Global Diabetic Nephropathy Market 2014-2018 with Merck & Co, Mitsubishi Tanabe Pharma, Novartis AG & Sanofi S.A. Dominating" report to their offering.
Global Diabetic Nephropathy Market 2014-2018 with Merck & Co, Mitsubishi Tanabe Pharma, Novartis AG & Sanofi S.A. Dominating
M2 - Wed Apr 09, 6:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/73nzx7/global_diabetic) has announced the addition of the "Global Diabetic Nephropathy Market 2014-2018 with Merck & Co, Mitsubishi Tanabe Pharma, Novartis AG & Sanofi S.A. Dominating" report to their offering. The Global Diabetic Nephropathy market will grow at a CAGR of 5% over the period 2013-2018. One of the main drivers in this market is the increase in the prevalence of diabetes. This has consequently led to an increase in the incidence of chronic kidney disease, the most common one being DN. The acceptability of DN drugs is expected to increase because of the increased public awareness about DN and the need for its treatment. This is expected to result in an increase in drug penetration. The increased general awareness about DN drugs has led to an increase in R&D funding and support for clinical and support services. For instance, the National Diabetes Education Program (NDEP) is jointly sponsored by the Centers for Disease Control and Prevention and the National Institutes of Health in the US. The NDEP's goal is to reduce the illness and death caused by diabetes and its complications. Similarly, several programs are organized by the American Diabetes Association to create awareness, prevent diabetes among at-risk populations, and ensure that all patients with diabetes get the best care, treatment, and information about diabetes management. Thus, the increased awareness about DN drugs is a new trend that is expected to auger well for the growth of the market during the forecast period. Further, the report states that one of the main challenges in this market is the increasing number of patent expirations. The patent expirations of major approved drugs will slow down the market growth during the forecast period. Key Vendors - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Sanofi S.A. Key Market Drivers/Challenges/Trends - Increase in Prevalence of Diabetes. - Increasing Number of Patent Expirations. - Increase in Awareness of Diabetic Nephropathy Drugs. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Pipeline Snapshot - Rate of Incidence and Prevalence - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/73...l_diabetic
Surveyed U.S. Psychiatrists Would Prescribe EnVivo Pharmaceuticals' Encenicline to 25 Percent of their Patients with Cognitive Impairment Associated with Schizophrenia
PR Newswire - Mon Mar 31, 9:00AM CDT
Decision Resources Group finds that surveyed U.S. psychiatrists would prescribe EnVivo Pharmaceuticals/Bayer HealthCare/Mitsubishi Tanabe Pharma's encenicline to 25 percent of their patients with cognitive impairment associated with schizophrenia (CIAS). Assuming its promising--albeit preliminary--clinical profile is confirmed in ongoing Phase III studies, encenicline could become the first-ever therapy approved to treat this condition, fulfilling a major unmet need in the clinical management of schizophrenia. Surveyed psychiatrists also project patient shares of up to 20 percent for other emerging CIAS drugs, including AbbVie's ABT-126, Omeros's OMS-824, and Avineuro Pharmaceuticals' AVN-211.
Global Generic Drugs Market 2014-2018: Branded Drugs with Sales of Up to US$135 Billion to Go Off-Patent by 2015
M2 - Mon Mar 24, 6:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6q8j7g/global_generic) has announced the addition of the "Global Generic Drugs Market 2014-2018" report to their offering. The analysts forecast the Global Generic Drugs market to grow at a CAGR of 11.02 percent over the period 2013-2018. The patent expiry of top-selling drugs is one of the major drivers contributing to the growth of this market. The market is also witnessing an increase in mergers and acquistions. However, intense competition among vendors could squeeze profit margins, increase pricing pressure, and pose a challenge to the growth of this market. Key vendors dominating this space include Actavis plc, Mylan Inc., Novartis International AG (Sandoz), STADA Arzneimittel AG, and Teva Pharmaceutical Industries Ltd. Other vendors mentioned in the report are 3SBio Inc., Amgen Inc., Apotex Inc., AstraZeneca plc, Aurobindo Pharma Ltd., Baxter International Inc., Berlin-Chemie AG, Biocon Ltd., Biogen Idec Inc., Boehringer Ingelheim GmbH, Celltrion Inc., Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Dr. Reddy's Laboratories Ltd., Emcure Pharmaceuticals Ltd., Gedeon Richter plc, GlaxoSmithKline plc, Hospira Inc., Impax Laboratories Inc., Intas Pharmaceuticals Ltd., Lupin Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Par Pharmaceutical Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Roche Holding AG, Sanofi S.A., Wockhardt Ltd., and Zydus Cadila Healthcare Ltd. Commenting on the report, an analyst from the team said: Mergers and acquisitions has become the core growth strategy among many healthcare vendors; they help vendors grow rapidly and expand their businesses. The Global Generic Drugs market has witnessed a number of mergers and acquisitions among the leading vendors. Vendors have been primarily focusing on mergers and acquisitions to increase their scale, revenue, market share, and competitive advantage. For instance, in November 2012, Actavis acquired Watson Pharmaceuticals and became the third largest generic pharmaceutical company across the globe, with operations in more than 60 countries. In October 2013, Actavis acquired Warner Chilcott plc for approximately US$8.5 billion. Moreover, in 2011, Teva acquired Ratiopharm AG, a leading generic drug manufacturer in Europe, to maintain its position in the market. For more information visit http://www.researchandmarkets.com/research/6q...al_generic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Concise Analysis of the Future Prospects of Global Personalized Medicine Market
M2 - Tue Mar 04, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpctsr/future_prospects) has announced the addition of the "Concise Analysis of the Future Prospects of Global Personalized Medicine Market" report to their offering. Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Co. - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Danaher Corp. - Eli Lilly and Co. - Evotec AG - F. Hoffmann-La Roche Ltd. - GE Healthcare Ltd. - Genelex Corp. - GlaxoSmithKline plc - Hologic Inc. - Johnson & Johnson - Laboratory Corporation of America Holdings - Life Technologies Corp. - Merck KGaA - Mitsubishi Tanabe Pharma Corp. - Myriad Genetics Inc. - Novartis AG - Novartis AG - PerkinElmer Inc. - Pfizer Inc. - Pfizer Inc. - Quest Diagnostics Inc. - Sanofi S.A. - Sanofi S.A. - Siemens Healthcare - Sigma-Aldrich Corp. - Takeda Pharmaceutical Co. Ltd. - Teva Pharmaceutical Industries Ltd. - Thermo Fisher Scientific Inc. - Transgenomic Inc. For more information visit http://www.researchandmarkets.com/research/zp..._prospects
MediMabs Announces the Appointment of Two New Members of the Board of Directors
Marketwire - Thu Feb 20, 10:52AM CST
Ms. Sarita Benchimol, the President and Chief Executive Officer of MediMabs Inc., is pleased to announce the election to the MediMabs Board of Directors of Dr. Randal Chase PhD and Mr. R Martin Wong CPA, CA. Both individuals were elected at the company's shareholder meeting and will be joining the existing board of directors, which includes Dr. Phil Gold CC, OQ, MD, PhD, FRSCopyright, FRCPCopyright, MACP, Dr. Claudio Cuello OC, MD, DSc, FRSCopyright, Mr. Miguel Madanes Eng., and Ms. Sarita Benchimol MSc.
General Anxiety Disorder - Pipeline Review, H2 2013
M2 - Tue Jan 28, 3:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/45w2z8/general_anxiety) has announced the addition of the "General Anxiety Disorder - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for General Anxiety Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for General Anxiety Disorder. General Anxiety Disorder - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for General Anxiety Disorder. - A review of the General Anxiety Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the General Anxiety Disorder pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to Buy - Identify and understand important and diverse types of therapeutics under development for General Anxiety Disorder. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding General Anxiety Disorder pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - Edgemont Pharmaceuticals - H. Lundbeck - Mitsubishi Tanabe Pharma Corporation - Rottapharm|Madaus For more information visit http://www.researchandmarkets.com/research/45...al_anxiety About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Market Research: Depression - Pipeline Review, H2 2013
M2 - Fri Dec 06, 3:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/q2dd65/depression) has announced the addition of the "Depression - Pipeline Review, H2 2013" report to their offering. 'Depression - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Depression. Scope - A snapshot of the global therapeutic scenario for Depression. - A review of the Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Depression pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH AstraZeneca PLC GlaxoSmithKline plc Daiichi Sankyo Company, Ltd Taisho Pharmaceutical Co., Ltd. Takeda Pharmaceutical Company Limited Neurocrine Biosciences, Inc. Aphios Corporation Eisai Co., Ltd. H Lundbeck A/S Mitsubishi Tanabe Pharma Corporation Pfizer Inc. Sigma-Tau S.p.A. Addex Pharmaceuticals FAES Farma SA Anavex Life Sciences Corp. Karo Bio KunWha Pharmaceutical Co., Ltd. Newron Pharmaceuticals S.p.A. M et P Pharma AG Angelini Group Domain Therapeutics For more information visit http://www.researchandmarkets.com/research/q2dd65/depression About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Market Research: Secondary Hyperparathyroidism - Pipeline Review, H2 2013
M2 - Tue Dec 03, 3:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/db8lm5/secondary) has announced the addition of the "Secondary Hyperparathyroidism - Pipeline Review, H2 2013" report to their offering. 'Secondary Hyperparathyroidism - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Secondary Hyperparathyroidism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism. Scope - A snapshot of the global therapeutic scenario for Secondary Hyperparathyroidism. - A review of the Secondary Hyperparathyroidism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Secondary Hyperparathyroidism pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Amgen Inc. Nektar Therapeutics Astellas Pharma Inc. Mitsubishi Tanabe Pharma Corporation OPKO Health, Inc. NPS Pharmaceuticals, Inc. Deltanoid Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/db8lm5/secondary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Invokana (Type 2 Diabetes) - Forecast and Market Analysis to 2022
M2 - Thu Nov 28, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/wvj6kv/invokana_type_2) has announced the addition of the "Invokana (Type 2 Diabetes) - Forecast and Market Analysis to 2022" report to their offering. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians' efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. On March 29, 2013, the FDA approved Johnson & Johnson's Invokana (canagliflozin), the first-to-the-US-market SGLT-2 inhibitor for treatment of type 2 diabetes. Invokana is in-licensed from Mitsubishi Tanabe Pharma. Invokana's mechanism of action employs the inhibition of SGLT-2, a low-affinity, high-capacity glucose cotransporter that is almost exclusively expressed in the kidney cortex. Inhibition of SGLT-2 has been shown to block the body's capacity to reabsorb glucose via the kidney, leading to glucose elimination in the urine and a reduction in blood glucose levels. Scope - Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Invokana including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Invokana for the top ten countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China. Reasons to Buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of Invokana performance Key Topics Covered 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Invokana (canagliflozin) 7 Appendix For more information visit http://www.researchandmarkets.com/research/wv...ana_type_2 About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Covagen and Tanabe Research Laboratories Expand Strategic Research Collaboration for Development of Bispecific FynomAbs
PR Newswire - Thu Nov 21, 12:30AM CST
Covagen and Tanabe Research Laboratories U.S.A, Inc. (TRL), a fully owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), today announced that they expanded their strategic research collaboration. MTPC and TRL have nominated a first bispecific FynomAb for formal preclinical development which triggered an undisclosed milestone payment. MTPC and TRL also exercised an option for a second bispecific FynomAb program based on the parties' research and licensing agreement signed in October 2012. Under the agreement, Covagen will use its proprietary Fynomer-antibody platform to generate bispecific antibodies (FynomAbs) against a second target pair selected by TRL and MTPC.
Inflammatory Bowel Disease - Pipeline Review, H2 2013
M2 - Tue Nov 19, 3:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/g29c7q/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H2 2013" report to their offering. 'Inflammatory Bowel Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Bowel Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease. Scope - A snapshot of the global therapeutic scenario for Inflammatory Bowel Disease. - A review of the Inflammatory Bowel Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Inflammatory Bowel Disease pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Inflammatory Bowel Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Inflammatory Bowel Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: Introduction Inflammatory Bowel Disease Overview Therapeutics Development Companies Involved in Inflammatory Bowel Disease Therapeutics Development Inflammatory Bowel Disease - Therapeutics Assessment Drug Profiles Appendix Companies Mentioned - 4SC - AlbireoPharma - Addex Pharmaceuticals - Basilea Pharmaceutica - Biotec Pharmacon - Compugen - Emergent BioSolutions - Eisai - Ferring Pharmaceuticals - GlaxoSmithKline - Indus Biotech Private Limited - Inotek Pharmaceuticals - Jenrin Discovery - Johnson & Johnson - KYORIN Pharmaceutical - Karo Bio - Lycera - Morria Biopharmaceuticals - Mitsubishi Tanabe Pharma - N30 Pharmaceuticals - Nephrx Corporation - Ono Pharmaceutical - Onyx Pharmaceuticals - PepTcell Limited - Paratek Pharmaceuticals - RaQualia Pharma - Rigel Pharmaceuticals - Santarus, Inc. - Synergy Pharmaceuticals - TiGenix NV - Upsher-Smith Laboratories - VentiRx Pharmaceuticals - Ventria Bioscience - Vitae Pharmaceuticals - Zealand Pharma A/S - iCo Therapeutics For more information visit http://www.researchandmarkets.com/research/g2...flammatory
Ischemic Stroke Drug Pipeline Report, H2 2013 Review
M2 - Wed Nov 06, 10:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/bpg5ck/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H2 2013" report to their offering. 'Ischemic Stroke - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ischemic Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ischemic Stroke. Scope - A snapshot of the global therapeutic scenario for Ischemic Stroke. - A review of the Ischemic Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ischemic Stroke pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned - Athersys, Inc. - Merck & Co., Inc. - FibroGen, Inc. - Laboratoires Pierre Fabre SA - Mitsubishi Tanabe Pharma Corporation - Pfizer Inc. - Celgene Corporation - Neuralstem, Inc. - Cytomedix, Inc. - Torrent Pharmaceuticals Limited - Pluristem Therapeutics Inc. - NeuroVive Pharmaceutical AB - SynZyme Technologies, LLC - AGY Therapeutics, Inc. - Angion Biomedica Corp. - Stemedica Cell Technologies, Inc. - Shin Poong Pharm Co., Ltd. For more information visit http://www.researchandmarkets.com/research/bp...mic_stroke
Mitsubishi Tanabe Pharma Completes Acquisiton of Medicago
PR Newswire - Wed Sep 18, 6:50AM CDT
Mitsubishi Tanabe Pharma Corporation (TSE: 4508) ("Mitsubishi Tanabe Pharma" or "MTPC"
and Medicago Inc. (TSX:MDG) announced today the completion of the previously announced acquisition of Medicago Inc. by MTPC.
Medicago Announces Receipt of Final Court Order and Regulatory Approvals for Arrangement with Mitsubishi Tanabe Pharma
PR Newswire - Thu Sep 12, 6:00AM CDT
Medicago Inc. (TSX: MDG; OTCQX: MDCGF) ("Medicago" or the "Company" , a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), is pleased to announce that the Superior Court of Quebec has granted its final order approving the previously announced plan of arrangement (the "Arrangement" involving the Company, Mitsubishi Tanabe Pharma Corporation ("MTPC" and 9284-9686 Québec Inc., a wholly-owned subsidiary of MTPC (the "Purchaser" .
Global Generic Drugs Market 2014-2018
PR Newswire Europe - Thu May 01, 8:16AM CDT
DUBLIN, May 1, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/sdjlqk/global_generic [http://www.researchandmarkets.com/research/sdjlqk/global_generic]) has announced the addition of the "Global Generic Drugs Market 2014-2018" [http://www.researchandmarkets.com/research/sdjlqk/global_generic] report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 [http://photos.prnewswire.com/prnh/20130307/600769]
Research and Markets: Global Amyotrophic Lateral Sclerosis Market 2014-2018 with Covis Pharmaceutical, Eisai, GSK & Mitsubishi Tanabe Pharma Dominating
Business Wire - Tue Apr 22, 5:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dnrs39/global) has announced the addition of the "Global Amyotrophic Lateral Sclerosis Market 2014-2018 with Covis Pharmaceutical, Eisai, GSK & Mitsubishi Tanabe Pharma Dominating" report to their offering.
Global Amyotrophic Lateral Sclerosis Market 2014-2018 with Covis Pharmaceutical, Eisai, GSK & Mitsubishi Tanabe Pharma Dominating
M2 - Tue Apr 22, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8ckvd2/global) has announced the addition of the "Global Amyotrophic Lateral Sclerosis Market 2014-2018 with Covis Pharmaceutical, Eisai, GSK & Mitsubishi Tanabe Pharma Dominating" report to their offering. One of the main drivers in this market is the increase in the aging population. The number of patients suffering from ALS is increasing due to its relatively high prevalence in the elderly population. The acceptability of ALS drugs is expected to rise due to increasing public awareness of ALS and associated disorders. This is expected to result in increasing drug penetration. Rising general awareness about ALS has led to an increase in research funding and support for clinical and support services. For instance, May is celebrated as ALS awareness month. The ALS Association strives to involve and engage patients and families in the process of increasing awareness and advocating for legislative changes. Similarly, CDMRP also organizes the ALS Research Program. The global research effort through this program has helped increase the number of scientists working on ALS, advanced new discoveries and treatments, and has shed light on the complex genetic and environmental factors involved in ALS. Further, the report states that one of the main challenges is the patent expiry of Rilutek. The patent expiry of Rilutek, the only marketed drug for the treatment of ALS, will result in the loss of market exclusivity. Key vendors dominating this space include - Covis Pharmaceutical Inc. - Eisai Co. Ltd. - GlaxoSmithKline plc - Mitsubishi Tanabe Pharma Corp. Other vendors mentioned in the report are - Amorfix Life Sciences Ltd. - BrainStrom Cell Therapeutics Inc. - Newron Pharmaceuticals S.p.A - Neuraltus Pharmaceuticals Inc. - Nutra Pharma Corp. - Oxford BioMedica plc - Pharnext SAS - Q-Therapeutics Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Buying Criteria - Rate of Incidence and Prevalence - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Late Stage Pipeline Snapshot - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/8ckvd2/global
Research and Markets: Global Diabetic Nephropathy Market 2014-2018 with Merck & Co, Mitsubishi Tanabe Pharma, Novartis AG & Sanofi S.A. Dominating
Business Wire - Wed Apr 09, 8:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pbwmcj/global_diabetic) has announced the addition of the "Global Diabetic Nephropathy Market 2014-2018 with Merck & Co, Mitsubishi Tanabe Pharma, Novartis AG & Sanofi S.A. Dominating" report to their offering.
Global Diabetic Nephropathy Market 2014-2018 with Merck & Co, Mitsubishi Tanabe Pharma, Novartis AG & Sanofi S.A. Dominating
M2 - Wed Apr 09, 6:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/73nzx7/global_diabetic) has announced the addition of the "Global Diabetic Nephropathy Market 2014-2018 with Merck & Co, Mitsubishi Tanabe Pharma, Novartis AG & Sanofi S.A. Dominating" report to their offering. The Global Diabetic Nephropathy market will grow at a CAGR of 5% over the period 2013-2018. One of the main drivers in this market is the increase in the prevalence of diabetes. This has consequently led to an increase in the incidence of chronic kidney disease, the most common one being DN. The acceptability of DN drugs is expected to increase because of the increased public awareness about DN and the need for its treatment. This is expected to result in an increase in drug penetration. The increased general awareness about DN drugs has led to an increase in R&D funding and support for clinical and support services. For instance, the National Diabetes Education Program (NDEP) is jointly sponsored by the Centers for Disease Control and Prevention and the National Institutes of Health in the US. The NDEP's goal is to reduce the illness and death caused by diabetes and its complications. Similarly, several programs are organized by the American Diabetes Association to create awareness, prevent diabetes among at-risk populations, and ensure that all patients with diabetes get the best care, treatment, and information about diabetes management. Thus, the increased awareness about DN drugs is a new trend that is expected to auger well for the growth of the market during the forecast period. Further, the report states that one of the main challenges in this market is the increasing number of patent expirations. The patent expirations of major approved drugs will slow down the market growth during the forecast period. Key Vendors - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Sanofi S.A. Key Market Drivers/Challenges/Trends - Increase in Prevalence of Diabetes. - Increasing Number of Patent Expirations. - Increase in Awareness of Diabetic Nephropathy Drugs. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Pipeline Snapshot - Rate of Incidence and Prevalence - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/73...l_diabetic
Surveyed U.S. Psychiatrists Would Prescribe EnVivo Pharmaceuticals' Encenicline to 25 Percent of their Patients with Cognitive Impairment Associated with Schizophrenia
PR Newswire - Mon Mar 31, 9:00AM CDT
Decision Resources Group finds that surveyed U.S. psychiatrists would prescribe EnVivo Pharmaceuticals/Bayer HealthCare/Mitsubishi Tanabe Pharma's encenicline to 25 percent of their patients with cognitive impairment associated with schizophrenia (CIAS). Assuming its promising--albeit preliminary--clinical profile is confirmed in ongoing Phase III studies, encenicline could become the first-ever therapy approved to treat this condition, fulfilling a major unmet need in the clinical management of schizophrenia. Surveyed psychiatrists also project patient shares of up to 20 percent for other emerging CIAS drugs, including AbbVie's ABT-126, Omeros's OMS-824, and Avineuro Pharmaceuticals' AVN-211.
Global Generic Drugs Market 2014-2018: Branded Drugs with Sales of Up to US$135 Billion to Go Off-Patent by 2015
M2 - Mon Mar 24, 6:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6q8j7g/global_generic) has announced the addition of the "Global Generic Drugs Market 2014-2018" report to their offering. The analysts forecast the Global Generic Drugs market to grow at a CAGR of 11.02 percent over the period 2013-2018. The patent expiry of top-selling drugs is one of the major drivers contributing to the growth of this market. The market is also witnessing an increase in mergers and acquistions. However, intense competition among vendors could squeeze profit margins, increase pricing pressure, and pose a challenge to the growth of this market. Key vendors dominating this space include Actavis plc, Mylan Inc., Novartis International AG (Sandoz), STADA Arzneimittel AG, and Teva Pharmaceutical Industries Ltd. Other vendors mentioned in the report are 3SBio Inc., Amgen Inc., Apotex Inc., AstraZeneca plc, Aurobindo Pharma Ltd., Baxter International Inc., Berlin-Chemie AG, Biocon Ltd., Biogen Idec Inc., Boehringer Ingelheim GmbH, Celltrion Inc., Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Dr. Reddy's Laboratories Ltd., Emcure Pharmaceuticals Ltd., Gedeon Richter plc, GlaxoSmithKline plc, Hospira Inc., Impax Laboratories Inc., Intas Pharmaceuticals Ltd., Lupin Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Par Pharmaceutical Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Roche Holding AG, Sanofi S.A., Wockhardt Ltd., and Zydus Cadila Healthcare Ltd. Commenting on the report, an analyst from the team said: Mergers and acquisitions has become the core growth strategy among many healthcare vendors; they help vendors grow rapidly and expand their businesses. The Global Generic Drugs market has witnessed a number of mergers and acquisitions among the leading vendors. Vendors have been primarily focusing on mergers and acquisitions to increase their scale, revenue, market share, and competitive advantage. For instance, in November 2012, Actavis acquired Watson Pharmaceuticals and became the third largest generic pharmaceutical company across the globe, with operations in more than 60 countries. In October 2013, Actavis acquired Warner Chilcott plc for approximately US$8.5 billion. Moreover, in 2011, Teva acquired Ratiopharm AG, a leading generic drug manufacturer in Europe, to maintain its position in the market. For more information visit http://www.researchandmarkets.com/research/6q...al_generic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Concise Analysis of the Future Prospects of Global Personalized Medicine Market
M2 - Tue Mar 04, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpctsr/future_prospects) has announced the addition of the "Concise Analysis of the Future Prospects of Global Personalized Medicine Market" report to their offering. Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Co. - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Danaher Corp. - Eli Lilly and Co. - Evotec AG - F. Hoffmann-La Roche Ltd. - GE Healthcare Ltd. - Genelex Corp. - GlaxoSmithKline plc - Hologic Inc. - Johnson & Johnson - Laboratory Corporation of America Holdings - Life Technologies Corp. - Merck KGaA - Mitsubishi Tanabe Pharma Corp. - Myriad Genetics Inc. - Novartis AG - Novartis AG - PerkinElmer Inc. - Pfizer Inc. - Pfizer Inc. - Quest Diagnostics Inc. - Sanofi S.A. - Sanofi S.A. - Siemens Healthcare - Sigma-Aldrich Corp. - Takeda Pharmaceutical Co. Ltd. - Teva Pharmaceutical Industries Ltd. - Thermo Fisher Scientific Inc. - Transgenomic Inc. For more information visit http://www.researchandmarkets.com/research/zp..._prospects
MediMabs Announces the Appointment of Two New Members of the Board of Directors
Marketwire - Thu Feb 20, 10:52AM CST
Ms. Sarita Benchimol, the President and Chief Executive Officer of MediMabs Inc., is pleased to announce the election to the MediMabs Board of Directors of Dr. Randal Chase PhD and Mr. R Martin Wong CPA, CA. Both individuals were elected at the company's shareholder meeting and will be joining the existing board of directors, which includes Dr. Phil Gold CC, OQ, MD, PhD, FRSCopyright, FRCPCopyright, MACP, Dr. Claudio Cuello OC, MD, DSc, FRSCopyright, Mr. Miguel Madanes Eng., and Ms. Sarita Benchimol MSc.
General Anxiety Disorder - Pipeline Review, H2 2013
M2 - Tue Jan 28, 3:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/45w2z8/general_anxiety) has announced the addition of the "General Anxiety Disorder - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for General Anxiety Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for General Anxiety Disorder. General Anxiety Disorder - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for General Anxiety Disorder. - A review of the General Anxiety Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the General Anxiety Disorder pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to Buy - Identify and understand important and diverse types of therapeutics under development for General Anxiety Disorder. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding General Anxiety Disorder pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - Edgemont Pharmaceuticals - H. Lundbeck - Mitsubishi Tanabe Pharma Corporation - Rottapharm|Madaus For more information visit http://www.researchandmarkets.com/research/45...al_anxiety About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Market Research: Depression - Pipeline Review, H2 2013
M2 - Fri Dec 06, 3:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/q2dd65/depression) has announced the addition of the "Depression - Pipeline Review, H2 2013" report to their offering. 'Depression - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Depression. Scope - A snapshot of the global therapeutic scenario for Depression. - A review of the Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Depression pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH AstraZeneca PLC GlaxoSmithKline plc Daiichi Sankyo Company, Ltd Taisho Pharmaceutical Co., Ltd. Takeda Pharmaceutical Company Limited Neurocrine Biosciences, Inc. Aphios Corporation Eisai Co., Ltd. H Lundbeck A/S Mitsubishi Tanabe Pharma Corporation Pfizer Inc. Sigma-Tau S.p.A. Addex Pharmaceuticals FAES Farma SA Anavex Life Sciences Corp. Karo Bio KunWha Pharmaceutical Co., Ltd. Newron Pharmaceuticals S.p.A. M et P Pharma AG Angelini Group Domain Therapeutics For more information visit http://www.researchandmarkets.com/research/q2dd65/depression About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Market Research: Secondary Hyperparathyroidism - Pipeline Review, H2 2013
M2 - Tue Dec 03, 3:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/db8lm5/secondary) has announced the addition of the "Secondary Hyperparathyroidism - Pipeline Review, H2 2013" report to their offering. 'Secondary Hyperparathyroidism - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Secondary Hyperparathyroidism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism. Scope - A snapshot of the global therapeutic scenario for Secondary Hyperparathyroidism. - A review of the Secondary Hyperparathyroidism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Secondary Hyperparathyroidism pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Amgen Inc. Nektar Therapeutics Astellas Pharma Inc. Mitsubishi Tanabe Pharma Corporation OPKO Health, Inc. NPS Pharmaceuticals, Inc. Deltanoid Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/db8lm5/secondary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Invokana (Type 2 Diabetes) - Forecast and Market Analysis to 2022
M2 - Thu Nov 28, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/wvj6kv/invokana_type_2) has announced the addition of the "Invokana (Type 2 Diabetes) - Forecast and Market Analysis to 2022" report to their offering. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians' efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. On March 29, 2013, the FDA approved Johnson & Johnson's Invokana (canagliflozin), the first-to-the-US-market SGLT-2 inhibitor for treatment of type 2 diabetes. Invokana is in-licensed from Mitsubishi Tanabe Pharma. Invokana's mechanism of action employs the inhibition of SGLT-2, a low-affinity, high-capacity glucose cotransporter that is almost exclusively expressed in the kidney cortex. Inhibition of SGLT-2 has been shown to block the body's capacity to reabsorb glucose via the kidney, leading to glucose elimination in the urine and a reduction in blood glucose levels. Scope - Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Invokana including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Invokana for the top ten countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China. Reasons to Buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of Invokana performance Key Topics Covered 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Invokana (canagliflozin) 7 Appendix For more information visit http://www.researchandmarkets.com/research/wv...ana_type_2 About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Covagen and Tanabe Research Laboratories Expand Strategic Research Collaboration for Development of Bispecific FynomAbs
PR Newswire - Thu Nov 21, 12:30AM CST
Covagen and Tanabe Research Laboratories U.S.A, Inc. (TRL), a fully owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), today announced that they expanded their strategic research collaboration. MTPC and TRL have nominated a first bispecific FynomAb for formal preclinical development which triggered an undisclosed milestone payment. MTPC and TRL also exercised an option for a second bispecific FynomAb program based on the parties' research and licensing agreement signed in October 2012. Under the agreement, Covagen will use its proprietary Fynomer-antibody platform to generate bispecific antibodies (FynomAbs) against a second target pair selected by TRL and MTPC.
Inflammatory Bowel Disease - Pipeline Review, H2 2013
M2 - Tue Nov 19, 3:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/g29c7q/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H2 2013" report to their offering. 'Inflammatory Bowel Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Bowel Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease. Scope - A snapshot of the global therapeutic scenario for Inflammatory Bowel Disease. - A review of the Inflammatory Bowel Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Inflammatory Bowel Disease pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Inflammatory Bowel Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Inflammatory Bowel Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: Introduction Inflammatory Bowel Disease Overview Therapeutics Development Companies Involved in Inflammatory Bowel Disease Therapeutics Development Inflammatory Bowel Disease - Therapeutics Assessment Drug Profiles Appendix Companies Mentioned - 4SC - AlbireoPharma - Addex Pharmaceuticals - Basilea Pharmaceutica - Biotec Pharmacon - Compugen - Emergent BioSolutions - Eisai - Ferring Pharmaceuticals - GlaxoSmithKline - Indus Biotech Private Limited - Inotek Pharmaceuticals - Jenrin Discovery - Johnson & Johnson - KYORIN Pharmaceutical - Karo Bio - Lycera - Morria Biopharmaceuticals - Mitsubishi Tanabe Pharma - N30 Pharmaceuticals - Nephrx Corporation - Ono Pharmaceutical - Onyx Pharmaceuticals - PepTcell Limited - Paratek Pharmaceuticals - RaQualia Pharma - Rigel Pharmaceuticals - Santarus, Inc. - Synergy Pharmaceuticals - TiGenix NV - Upsher-Smith Laboratories - VentiRx Pharmaceuticals - Ventria Bioscience - Vitae Pharmaceuticals - Zealand Pharma A/S - iCo Therapeutics For more information visit http://www.researchandmarkets.com/research/g2...flammatory
Ischemic Stroke Drug Pipeline Report, H2 2013 Review
M2 - Wed Nov 06, 10:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/bpg5ck/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H2 2013" report to their offering. 'Ischemic Stroke - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ischemic Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ischemic Stroke. Scope - A snapshot of the global therapeutic scenario for Ischemic Stroke. - A review of the Ischemic Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ischemic Stroke pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned - Athersys, Inc. - Merck & Co., Inc. - FibroGen, Inc. - Laboratoires Pierre Fabre SA - Mitsubishi Tanabe Pharma Corporation - Pfizer Inc. - Celgene Corporation - Neuralstem, Inc. - Cytomedix, Inc. - Torrent Pharmaceuticals Limited - Pluristem Therapeutics Inc. - NeuroVive Pharmaceutical AB - SynZyme Technologies, LLC - AGY Therapeutics, Inc. - Angion Biomedica Corp. - Stemedica Cell Technologies, Inc. - Shin Poong Pharm Co., Ltd. For more information visit http://www.researchandmarkets.com/research/bp...mic_stroke
Mitsubishi Tanabe Pharma Completes Acquisiton of Medicago
PR Newswire - Wed Sep 18, 6:50AM CDT
Mitsubishi Tanabe Pharma Corporation (TSE: 4508) ("Mitsubishi Tanabe Pharma" or "MTPC"
and Medicago Inc. (TSX:MDG) announced today the completion of the previously announced acquisition of Medicago Inc. by MTPC. Medicago Announces Receipt of Final Court Order and Regulatory Approvals for Arrangement with Mitsubishi Tanabe Pharma
PR Newswire - Thu Sep 12, 6:00AM CDT
Medicago Inc. (TSX: MDG; OTCQX: MDCGF) ("Medicago" or the "Company"
, a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), is pleased to announce that the Superior Court of Quebec has granted its final order approving the previously announced plan of arrangement (the "Arrangement" involving the Company, Mitsubishi Tanabe Pharma Corporation ("MTPC" and 9284-9686 Québec Inc., a wholly-owned subsidiary of MTPC (the "Purchaser" . 
